In Washington, biotech’s China hawks are winning the conversationnews2026-06-05T18:37:56+00:00June 5th, 2026|Endpoints News|
Industry seeks more clarity on commissioner’s voucher programnews2026-06-05T17:49:38+00:00June 5th, 2026|Endpoints News|
House committee directs FDA to speed up IND sign-off processnews2026-06-05T16:55:49+00:00June 5th, 2026|Endpoints News|
Innovent declares Phase 3 success for ADC that attracted huge Takeda dealnews2026-06-05T15:32:26+00:00June 5th, 2026|Endpoints News|
Fulcrum lays off majority of staff; Seres extends runway into 2027news2026-06-05T12:55:14+00:00June 5th, 2026|Endpoints News|
Novo vet Uli Stilz settles in at Flagship; Revolution Medicines welcomes commercial execnews2026-06-05T11:00:23+00:00June 5th, 2026|Endpoints News|
Otsuka touts new IgAN evidence as it seeks full approval for Voyxactnews2026-06-04T22:31:11+00:00June 4th, 2026|Endpoints News|
Acting FDA chief isn’t interested in permanent rolenews2026-06-04T19:42:30+00:00June 4th, 2026|Endpoints News|
Acting FDA commissioner pledges to prevent political interference in rare disease meetingnews2026-06-04T17:53:42+00:00June 4th, 2026|Endpoints News|
Dimension seeks up to $750M for third life sciences fund after string of successnews2026-06-04T17:05:08+00:00June 4th, 2026|Endpoints News|
